PMCB [NASD]
PharmaCyte Biotech, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own3.76% Shs Outstand21.67M Perf Week2.75%
Market Cap44.49M Forward P/E- EPS next Y-0.18 Insider Trans0.00% Shs Float19.94M Perf Month-3.03%
Income-3.80M PEG- EPS next Q-0.04 Inst Own23.80% Short Float1.30% Perf Quarter-2.61%
Sales- P/S- EPS this Y41.80% Inst Trans8.47% Short Ratio0.56 Perf Half Y-11.11%
Book/sh4.22 P/B0.53 EPS next Y25.00% ROA-7.60% Target Price- Perf Year-84.60%
Cash/sh4.36 P/C0.51 EPS next 5Y- ROE-7.70% 52W Range1.79 - 21.00 Perf YTD-10.40%
Dividend- P/FCF- EPS past 5Y27.20% ROI- 52W High-89.33% Beta0.02
Dividend %- Quick Ratio141.60 Sales past 5Y- Gross Margin- 52W Low25.14% ATR0.12
Employees4 Current Ratio141.60 Sales Q/Q- Oper. Margin- RSI (14)55.96 Volatility5.14% 5.86%
OptionableYes Debt/Eq0.00 EPS Q/Q92.30% Profit Margin- Rel Volume0.26 Prev Close2.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume462.33K Price2.24
Recom3.00 SMA204.78% SMA502.77% SMA200-8.48% Volume120,425 Change0.00%
Jun-23-22 09:00AM  
Jun-15-22 08:30AM  
Jun-13-22 08:30AM  
Jun-09-22 09:00AM  
Jun-08-22 08:30AM  
Jun-02-22 09:00AM  
May-23-22 09:00AM  
May-11-22 09:00AM  
Apr-27-22 09:00AM  
Apr-19-22 09:00AM  
Apr-13-22 09:00AM  
Apr-05-22 09:00AM  
Mar-22-22 09:00AM  
Mar-16-22 09:00AM  
Feb-22-22 09:00AM  
Feb-14-22 09:00AM  
Jan-06-22 09:00AM  
Jan-04-22 09:00AM  
Dec-28-21 09:00AM  
Dec-15-21 09:00AM  
Dec-08-21 10:16AM  
Nov-30-21 01:05AM  
Nov-12-21 09:00AM  
Sep-27-21 09:00AM  
Sep-21-21 09:00AM  
Sep-16-21 09:00AM  
Sep-08-21 09:00AM  
Aug-31-21 09:20AM  
Aug-25-21 09:00AM  
Aug-23-21 04:39PM  
Aug-19-21 07:19AM  
Aug-16-21 09:00AM  
Aug-12-21 03:00PM  
Aug-09-21 05:37PM  
Aug-02-21 04:58PM  
Jul-14-21 08:45AM  
Jul-13-21 07:57PM  
Jul-09-21 07:11PM  
Jul-08-21 09:00AM  
Jun-24-21 09:00AM  
Jun-22-21 09:00AM  
Jun-18-21 09:00AM  
Jun-14-21 09:00AM  
Apr-01-21 09:00AM  
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.